KPV: research overview

The short version

KPV is a tiny peptide — just three amino acids: lysine, proline and valine — that is itself a fragment of a larger natural hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). The parent hormone does several things in the body, including controlling pigmentation and calming inflammation. KPV keeps the anti-inflammatory piece of that activity while dropping the pigmentation effect entirely.

Most of the research on KPV looks at the gut lining, where a specific transporter shuttles the tripeptide directly into intestinal cells, and where inflamed tissue seems to take up more of it. That research is entirely in cell cultures and in mice — there are no published human trials of KPV for any use. This page reports the mechanism and the animal findings plainly, and it does not suggest KPV as a treatment or attach a dose for a person to anything written here.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to the C-terminal three residues (positions 11-13) of alpha-MSH. Its molecular formula is C16H30N4O4. Because it represents only the tail end of the parent hormone, it is sometimes labeled alpha-MSH(11-13) in the scientific literature.

KPV is classified as a melanocortin-derived anti-inflammatory tripeptide. It is not itself a melanocortin-receptor agonist in the way the full hormone is, and a mechanistic study specifically found that KPV's anti-inflammatory action does not depend on melanocortin receptors the way the core alpha-MSH sequence does, pointing instead toward a distinct pathway involving inhibition of interleukin-1beta (IL-1β) signaling ^[12].

How it works

KPV's research profile centers on two connected ideas: how it gets into cells, and what it does once inside them. In the gut, KPV is taken up directly by intestinal epithelial cells through PepT1 (SLC15A1), a transporter normally used to absorb small peptide fragments from digested protein — and PepT1 is upregulated in inflamed intestinal tissue, meaning KPV may be preferentially delivered to the areas that need it most ^[8].

Once inside relevant cells, nanomolar concentrations of KPV inhibit two central inflammatory signaling pathways — NF-κB and the MAP-kinase cascade — and reduce the secretion of pro-inflammatory cytokines, an effect demonstrated in both human intestinal epithelial cell lines and immune (Jurkat T) cells ^[8]. A broader review of alpha-MSH-derived tripeptides describes this NF-κB-suppressing, cytokine-reducing activity as the throughline across dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway and arthritic models where related short peptides have shown protective effects — while explicitly noting KPV keeps this anti-inflammatory function without the pigmentary action of the full hormone ^[10].

What the research shows

The strongest and most consistent KPV data come from mouse models of colitis. In one foundational study, orally administered KPV reduced the severity of both DSS-induced and TNBS-induced colitis in mice, alongside the in-vitro cytokine-suppression findings described above ^[8]. A separate group found that KPV-treated mice in a DSS colitis model recovered earlier and regained body weight significantly faster than untreated mice, with reduced colonic inflammatory infiltrate and lower myeloperoxidase activity (a marker of tissue-level immune-cell activity) — and this protective effect was retained even in mice lacking the MC1R melanocortin receptor, indicating the mechanism does not depend on classical melanocortin signaling ^[9].

Delivery is an active area of KPV research precisely because the free tripeptide is small and easily broken down by digestive enzymes before it can act. A 2024 study co-assembled KPV with the immunosuppressant FK506 into a PepT1-targeted nanoparticle and found it improved both acute and chronic colitis in mice beyond either agent alone, restoring tight-junction proteins in the gut lining and lowering inflammatory cytokines ^[6]. An earlier formulation embedded KPV in hyaluronic-acid-functionalized nanoparticles within a chitosan/alginate hydrogel for oral delivery, and this targeted approach reduced mucosal damage and downregulated tumor necrosis factor-alpha more effectively than a non-targeted KPV formulation, accelerating mucosal healing in the same DSS colitis model ^[7].

Outside the gut, KPV's anti-inflammatory activity has also been studied topically: applied to rabbit corneas after an epithelial injury, KPV accelerated wound closure, with all eight treated corneas fully re-epithelialized by 60 hours compared with none of the placebo-treated corneas, an effect the authors linked to a nitric-oxide-dependent mechanism ^[11]. Mechanistic work in cultured macrophages and a mouse peritonitis model further distinguished KPV's action from that of the core alpha-MSH peptides, finding it reduces immune-cell accumulation without suppressing macrophage cytokine release the way the parent sequence does — evidence for a mechanistically distinct, likely IL-1β-directed pathway ^[12].

Reported effects, cautions & safety

The corpus behind this hub records no community-reported effects and no compiled safety cautions specific to KPV, and this page will not invent any. What can be said plainly, grounded in the peer-reviewed literature, is this: no published human clinical trial of KPV exists for any indication, so its efficacy, dosing and safety profile in people are entirely unestablished ^[8][9][10]. Free KPV is a small tripeptide that is readily broken down by digestive and tissue enzymes, and much of the recent research effort — the nanoparticle and hydrogel delivery work described above — exists specifically to solve that stability problem well enough to study the peptide at all ^[6][7].

Because KPV derives from alpha-MSH, it is sometimes confused with melanocortin agonists used for pigmentation or tanning; the literature is clear that KPV's defining property is anti-inflammatory activity without the pigmentary effect of the parent hormone ^[10]. KPV is supplied by chemical vendors strictly for laboratory research and is not an approved drug or dietary supplement in any major jurisdiction, and any human-use framing outruns what the current evidence — mechanistic and preclinical — actually supports.

Where it fits in recovery & tissue repair

As the lead compound on this desk, KPV represents the gut-mucosa and cytokine-suppression end of the recovery picture — a counterpart to TB-500's migration-and-angiogenesis mechanism. Its PepT1-mediated, tissue-selective uptake and NF-κB-suppressing action are the rationale for including it in the KLOW blend alongside TB-500, GHK-Cu and BPC-157. See the comparison page for how KPV's exclusively preclinical evidence base compares with the other two compounds on this site.